|
MRPL30 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.12840004007353E-09 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.30809999498993E-08 |
| Normal-vs-Stage2 |
4.015100E-03 |
| Normal-vs-Stage3 |
1.27139999972492E-07 |
| Normal-vs-Stage4 |
4.91829998949811E-09 |
| Stage1-vs-Stage2 |
9.328000E-02 |
| Stage1-vs-Stage3 |
7.870800E-01 |
| Stage1-vs-Stage4 |
7.868300E-02 |
| Stage2-vs-Stage3 |
8.598100E-02 |
| Stage2-vs-Stage4 |
8.921900E-03 |
| Stage3-vs-Stage4 |
1.992450E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.90420013090886E-10 |
| Normal-vs-AfricanAmerican |
3.359700E-03 |
| Normal-vs-Asian |
3.57300000000116E-05 |
| Caucasian-vs-AfricanAmerican |
3.063000E-01 |
| Caucasian-vs-Asian |
6.387000E-01 |
| AfricanAmerican-vs-Asian |
5.557800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.60459999731799E-08 |
| Normal-vs-Female |
7.31990001945348E-09 |
| Male-vs-Female |
3.364600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
3.58249999665716E-08 |
| Normal-vs-Age(41-60Yrs) |
1.74649994466591E-09 |
| Normal-vs-Age(61-80Yrs) |
8.41240000000187E-05 |
| Normal-vs-Age(81-100Yrs) |
1.016410E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
7.964400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.780570E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.944000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.785800E-02 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.554600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.265800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
9.195000E-01 |
| Classical-VS-Follicular |
3.991800E-01 |
| Classical-VS-Other |
4.900800E-01 |
| Classical-VS-Normal |
3.71810027210984E-10 |
| Tall-VS-Follicular |
5.031400E-01 |
| Tall-VS-Other |
5.806800E-01 |
| Tall-VS-Normal |
1.568670E-04 |
| Follicular-VS-Other |
4.639800E-01 |
| Follicular-VS-Normal |
4.847300E-04 |
| Other-VS-Normal |
9.501900E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
8.9352999999015E-08 |
| Normal-vs-N1 |
1.00899999466719E-09 |
| N0-vs-N1 |
1.197820E-02 |
|
|
